1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Seagen Inc.
  6. News
  7. Summary
    SGEN   US81181C1045


SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Seagen Inc. Announces Data from Phase I Clinical Trial Combining SEA-CD40

01/18/2022 | 05:00pm EDT

Seagen Inc. announced data from a phase 1 clinical trial combining SEA-CD40 with chemotherapy and an anti-PD-1 in patients with metastatic PDAC at the ASCO GI annual meeting taking place in San Francisco, January 20 – 22, 2022. SEA-CD40 is a novel, investigational, nonfucosylated monoclonal receptor-agonistic antibody directed to CD40, which is expressed on antigen-presenting cells. In preclinical models, the combination of SEA-CD40 and chemotherapy resulted in antitumor activity which is further enhanced with anti-PD-1 treatment. In the ongoing phase 1 trial, SEA-CD40 was combined with chemotherapy [gemcitabine and nab-paclitaxel (GnP)], and an anti-PD-1 (pembrolizumab), in 61 patients with untreated metastatic PDAC. Of these, 40 patients received 10 mcg/kg and 21 patients received 30 mcg/kg of SEA-CD40. Key endpoints include confirmed objective response rate (cORR) per RECIST v1.1 by investigator, progression-free survival (PFS) and overall survival (OS). Activity of SEA-CD40 in combination with GnP and pembrolizumab was observed in both doses of SEA-CD40 tested. The overall (N = 61) cORR was 44 percent, median PFS was 7.4 months (95% CI: 5.6-9.0), and median OS was 15.0 months (95 percent CI: 7.8-19.9). Follow-up for efficacy is ongoing. The regimen demonstrated a manageable and tolerable safety profile. Overall, = grade 3 treatment-emergent adverse events (TEAEs) were fatigue, nausea, neutropenia, infusion-related reaction, chills, diarrhea, and pyrexia. This combination also showed evidence of immune activation consistent with the SEA-CD40 mechanism of action.

ę S&P Capital IQ 2022
All news about SEAGEN INC.
05/27INSIDER SELL : Seagen
05/26Takeda Pharmaceutical Company Limited and Seagen Inc. to Highlight ADCETRIS« Combinatio..
05/23Seagen Sees Positive Topline Data From Study of Tukysa With Trastuzumab in HER2-Positiv..
05/23SEAGEN : Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA« (..
05/23SEAGEN INC. : Other Events, Financial Statements and Exhibits (form 8-K)
05/23Seagen Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUKYSA« ..
05/23Seagen Inc. Announces Positive Topline Results of Pivotal Phase 2 Clinical Trial of TUK..
05/23SEAGEN INC. : SEC Filing 8K
05/19SEAGEN INC. : Submission of Matters to a Vote of Security Holders (form 8-K)
05/16US Stocks Begin Week Mostly Lower Amid Empire State Manufacturing Weakness
More news
Analyst Recommendations on SEAGEN INC.
More recommendations
Financials (USD)
Sales 2022 1 793 M - -
Net income 2022 -651 M - -
Net cash 2022 1 615 M - -
P/E ratio 2022 -39,9x
Yield 2022 -
Capitalization 26 026 M 26 026 M -
EV / Sales 2022 13,6x
EV / Sales 2023 9,62x
Nbr of Employees 2 675
Free-Float 99,2%
Duration : Period :
Seagen Inc. Technical Analysis Chart | SGEN | US81181C1045 | MarketScreener
Technical analysis trends SEAGEN INC.
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 20
Last Close Price 141,39 $
Average target price 160,94 $
Spread / Average Target 13,8%
EPS Revisions
Managers and Directors
Roger D. Dansey Chief Executive & Medical Officer
Todd E. Simpson Chief Financial Officer
Felix James Baker Chairman
Vaughn B. Himes Chief Technical Officer
David W. Gryska Independent Director
Sector and Competitors
1st jan.Capi. (M$)
SEAGEN INC.-8.54%26 026
MODERNA, INC.-41.86%58 733
LONZA GROUP AG-24.79%44 437
IQVIA HOLDINGS INC.-21.85%41 736
CELLTRION, INC.-21.21%17 245